In Law360, Shanghai Attorneys Examine China FDA Reform Encouraging Drug and Device Innovation
Life sciences partner Katherine Wang (Shanghai) co-authored a Nov. 15 Law360 article that examines the China Food and Drug Administration’s (CFDA) final regulatory reform policy that encourages life sciences innovation in China.
The authors explain how the CFDA policies reflect the Chinese government’s unprecedented determination to accelerate drug and device approvals while deregulating the conduct of clinical research studies.